Patents by Inventor Xiaozhao Wang

Xiaozhao Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bicyclic amines as CDK2 inhibitors
    Patent number: 11976073
    Abstract: The present application provides bicyclic amines of Formula (I): and their pharmaceutically acceptable salts thereof, that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Grant
    Filed: December 9, 2022
    Date of Patent: May 7, 2024
    Assignee: Incyte Corporation
    Inventors: Joshua Hummel, David M. Burns, Ding-Quan Qian, Xiaozhao Wang
  • PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS
    Publication number: 20240124463
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Application
    Filed: January 9, 2023
    Publication date: April 18, 2024
    Inventors: Yun-Long Li, Xiaozhao Wang, Joseph Barbosa, David M. Burns, Hao Feng, Joseph Glenn, Chunhong He, Taisheng Huang, Song Mei, Jincong Zhuo
  • FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12V MUTANTS
    Publication number: 20240101557
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: July 10, 2023
    Publication date: March 28, 2024
    Inventors: GENCHENG LI, LEI LIU, PEI GAN, CHANG MIN, ALEXANDER SOKOLSKY, XIAOZHAO WANG, QINDA YE, LE ZHAO
  • Quinoline compounds as inhibitors of KRAS
    Patent number: 11939328
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Grant
    Filed: October 13, 2022
    Date of Patent: March 26, 2024
    Assignee: Incyte Corporation
    Inventors: Qinda Ye, Matthew McCammant, Artem Shvartsbart, Wenyu Zhu, Bin Hu, Chao Qi, Xiaozhao Wang, Wenqing Yao, Alexander Sokolsky
  • TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS
    Publication number: 20240083898
    Abstract: The present application provides tricyclic triazolo compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: August 11, 2023
    Publication date: March 14, 2024
    Inventors: Joshua Hummel, Ding-Quan Qian, Xiaozhao Wang, Meizhong Xu
  • TETRACYCLIC COMPOUNDS AS DGK INHIBITORS
    Publication number: 20240034734
    Abstract: The present application provides tetracyclic compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: July 17, 2023
    Publication date: February 1, 2024
    Inventors: Joshua Hummel, Shicheng Shi, Xiaozhao Wang
  • Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors
    Patent number: 11884665
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: June 15, 2022
    Date of Patent: January 30, 2024
    Assignee: Incyte Corporation
    Inventors: Taisheng Huang, Xiaozhao Wang
  • TETRACYCLIC COMPOUNDS AS DGK INHIBITORS
    Publication number: 20240025900
    Abstract: The present application provides tetracyclic compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: July 17, 2023
    Publication date: January 25, 2024
    Inventors: Joshua Hummel, Shicheng Shi, Xiaozhao Wang
  • Fused pyrimidine derivatives as A2A/A2B inhibitors
    Patent number: 11873304
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: January 27, 2021
    Date of Patent: January 16, 2024
    Assignee: Incyte Corporation
    Inventors: Xiaozhao Wang, Heeoon Han, Matthew S. McCammant, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Le Zhao
  • TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS
    Publication number: 20230399342
    Abstract: The present application provides tricyclic triazolo compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: June 7, 2023
    Publication date: December 14, 2023
    Inventors: Joshua Hummel, Liana Hie, Jacob J. Lacharity, Xiaolei Li, Sharada Manns, Ding-Quan Qian, Xiaozhao Wang, Bo Wei, Meizhong Xu
  • IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS
    Publication number: 20230357255
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: April 13, 2023
    Publication date: November 9, 2023
    Inventors: Xiaozhao Wang, Pei Gan, Taisheng Huang, Chao Qi, Ding-Quan Qian, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Fenglei Zhang, Le Zhao, Chunhong He
  • Bicyclic dione compounds as inhibitors of KRAS
    Patent number: 11767320
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Grant
    Filed: October 1, 2021
    Date of Patent: September 26, 2023
    Assignee: INCYTE CORPORATION
    Inventors: Taisheng Huang, Xiaozhao Wang, Wenqing Yao
  • Fused pyrimidine compounds as KRAS inhibitors
    Patent number: 11739102
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Grant
    Filed: May 12, 2021
    Date of Patent: August 29, 2023
    Assignee: INCYTE CORPORATION
    Inventors: Gia Hoang, Xiaozhao Wang, Wenqing Yao
  • COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A KRAS INHIBITOR
    Publication number: 20230226040
    Abstract: The present disclosure relates to methods of treating cancer by administering a compound, which is a Fibroblast Growth Factor Receptor (FGFR) inhibitor, in combination with a Kirsten rat sarcoma (KRAS) inhibitor.
    Type: Application
    Filed: November 21, 2022
    Publication date: July 20, 2023
    Inventors: Alejandro Amador Arjona, Angela Abdollahi, Margaret Favata, Jonathan Rios-Doria, Hui Wang, Susan Wee, Pei Gan, Jeffrey C. Yang, Yong Li, Le Zhao, Chunhong He, Chunyin Marshall Law, Wenyu Zhu, Xiaozhao Wang, Wenqing Yao, Peter Niels Carlsen, Fenglei Zhang, Qinda Ye, Matthew S. McCammant, Rocco Policarpo, Artem Shvartsbart, Jeremy Roach, Gia Hoang, Bin Hu, Gencheng Li, Robert Susick, Padmaja Polam, Chao Qi, Alexander Sokolsky, Haolin Yin, Chang Min
  • BICYCLIC AMINES AS CDK2 INHIBITORS
    Publication number: 20230192706
    Abstract: The present application provides bicyclic amines of Formula (I): and their pharmaceutically acceptable salts thereof, that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: December 9, 2022
    Publication date: June 22, 2023
    Inventors: Joshua Hummel, David M. Burns, Ding-Quan Qian, Xiaozhao Wang, Ming Xiang, Jingwei Li
  • SPIRO COMPOUNDS AS INHIBITORS OF KRAS
    Publication number: 20230192696
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: November 3, 2022
    Publication date: June 22, 2023
    Inventors: Le ZHAO, Xiaozhao WANG, Wenyu ZHU, Haolin YIN, Liangxing WU, Wenqing YAO
  • BICYCLIC AMINES AS CDK2 INHIBITORS
    Publication number: 20230183250
    Abstract: The present application provides bicyclic amines of Formula (I): and their pharmaceutically acceptable salts thereof, that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: December 9, 2022
    Publication date: June 15, 2023
    Inventors: Joshua Hummel, David M. Burns, Ding-Quan Qian, Xiaozhao Wang
  • Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
    Patent number: 11673894
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: June 13, 2023
    Assignee: Incyte Corporation
    Inventors: Xiaozhao Wang, Pei Gan, Taisheng Huang, Chao Qi, Ding-Quan Qian, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Fenglei Zhang, Le Zhao, Chunhong He
  • NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF KRAS
    Publication number: 20230174555
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: August 30, 2022
    Publication date: June 8, 2023
    Inventors: Gencheng Li, Haolin Yin, Chao Qi, Xiaozhao Wang, Wenqing Yao, Bin Hu, Peter Carlsen
  • HETERO-TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS
    Publication number: 20230151005
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: September 20, 2022
    Publication date: May 18, 2023
    Inventors: Peter Carlsen, Ken Mukai, Haolin Yin, Xiaozhao Wang, Wenqing Yao, Wenyu Zhu